OptimizeRx’s (OPRX) “Buy” Rating Reiterated at B. Riley Financial

B. Riley Financial restated their buy rating on shares of OptimizeRx (NASDAQ:OPRX) in a report released on Friday morning,Benzinga reports. The firm currently has a $11.00 target price on the stock, down from their prior target price of $28.00.

A number of other research analysts have also recently issued reports on OPRX. Weiss Ratings reiterated a “sell (d+)” rating on shares of OptimizeRx in a research note on Monday, December 22nd. Wall Street Zen raised OptimizeRx from a “buy” rating to a “strong-buy” rating in a report on Sunday, December 14th. Stifel Nicolaus cut their price objective on OptimizeRx from $21.00 to $17.00 and set a “buy” rating for the company in a research report on Friday. Stephens reduced their price objective on OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Friday. Finally, Citizens Jmp increased their target price on OptimizeRx from $23.00 to $24.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $17.57.

OptimizeRx Stock Down 10.5%

OPRX opened at $6.74 on Friday. The firm has a market cap of $125.63 million, a price-to-earnings ratio of 25.92 and a beta of 1.21. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.05 and a current ratio of 3.04. The firm’s 50-day simple moving average is $10.52 and its 200-day simple moving average is $14.72. OptimizeRx has a twelve month low of $3.99 and a twelve month high of $22.25.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings results on Saturday, January 31st. The company reported $0.51 EPS for the quarter. OptimizeRx had a net margin of 4.69% and a return on equity of 10.61%. Equities research analysts anticipate that OptimizeRx will post -0.33 EPS for the current fiscal year.

OptimizeRx declared that its Board of Directors has initiated a share buyback program on Thursday, March 5th that authorizes the company to buyback $10.00 million in outstanding shares. This buyback authorization authorizes the company to repurchase up to 6.8% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s management believes its shares are undervalued.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC lifted its holdings in OptimizeRx by 600.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock worth $29,000 after buying an additional 1,818 shares in the last quarter. Quantbot Technologies LP bought a new position in OptimizeRx in the 2nd quarter valued at $44,000. BNP Paribas Financial Markets increased its stake in shares of OptimizeRx by 119.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after buying an additional 2,215 shares during the period. State of Alaska Department of Revenue acquired a new stake in shares of OptimizeRx in the 4th quarter valued at $62,000. Finally, USA Financial Formulas bought a new stake in shares of OptimizeRx during the third quarter worth $131,000. Institutional investors own 76.47% of the company’s stock.

Trending Headlines about OptimizeRx

Here are the key news stories impacting OptimizeRx this week:

• Positive Sentiment: Q4 earnings and revenue beat expectations — OPRX reported stronger-than-expected results (EPS and revenue topped consensus), supporting the company’s underlying growth narrative. Q4 Results
• Positive Sentiment: Board authorized a $10.0M share repurchase program (up to ~6.8% of shares), a shareholder-friendly move that typically supports share price over time by reducing float. Buyback Announcement
• Neutral Sentiment: Roth MKM lowered its price target from $32 to $18 but kept a “buy” rating — still a materially higher target than current levels, creating mixed signals (cut in optimism but continued buy conviction). Roth MKM PT Change
• Neutral Sentiment: Multiple brief trading halts for OPRX were reported today due to LULD pauses — technical market safeguards that can amplify volatility but do not convey fundamental news.
• Negative Sentiment: FY2026 revenue guidance came in at $109M–$114M versus consensus near $122M — a notable shortfall that likely drove investor disappointment and downward pressure on the stock. Guidance Story
• Negative Sentiment: B. Riley reaffirmed its buy rating but cut its price target from $28 to $11 — another analyst reduction that removes prior upside and likely contributed to selling pressure. B. Riley PT Cut
• Negative Sentiment: Stephens trimmed its target to $10 and set an “equal weight” rating, signaling a more cautious view and reducing analyst-driven upside expectations. Stephens PT Change

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.